Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Selective kinase and immune checkpoint inhibitors, and their combinations, have significantly improved the survival of patients with advanced metastatic melanoma. Not all patients will respond to treatment however, and some patients will present with significant toxicities. Hence, the identification of biomarkers is critical for the selection and management of patients receiving treatment. Biomarker discovery often involves proteomic techniques that simultaneously profile multiple proteins but few studies have compared these platforms. METHODS: In this study, we used the multiplex bead-based Eve Technologies Discovery assay and the aptamer-based SomaLogic SOMAscan assay to identify circulating proteins predictive of response to immunotherapy in melanoma patients treated with combination immune checkpoint inhibitors. Expression of four plasma proteins were further validated using the bead-based Millipore Milliplex assay. RESULTS: Both the Discovery and the SOMAscan assays detected circulating plasma proteins in immunotherapy-treated melanoma patients. However, these widely used assays showed limited correlation in relative protein quantification, due to differences in specificity and the dynamic range of protein detection. Protein data derived from the Discovery and Milliplex bead-based assays were highly correlated. CONCLUSIONS: Our study highlights significant limitations imposed by inconsistent sensitivity and specificity due to differences in the detection antibodies or aptamers of these widespread biomarker discovery approaches. Our findings emphasize the need to improve these technologies for the accurate identification of biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345 · cited 1×
“Cancer patients are currently being treated with new generations and combinations of targeted drugs [1, 2] and immunotherapy [3, 4] but, the activity of these drugs is hampered by variable response rates and the development of treatment resistance [5–7].”
BackgroundAptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754 · cited 1×
“The SOMAscan assay uses SOMAmer (Slow Off-rate Modified Aptamer) reagents, which consist of modified short DNA sequences that bind specific protein analytes [16].”
MethodClinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Alix-Panabières, C., & Pantel, K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1483 · Cited by 1,394
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294 · cited 1×
“Cancer patients are currently being treated with new generations and combinations of targeted drugs [1, 2] and immunotherapy [3, 4] but, the activity of these drugs is hampered by variable response rates and the development of treatment resistance [5–7].”
BackgroundHodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30366-7 · Cited by 968 · cited 1×
“However, the benefit of this drug combination comes with significant toxicity and 40% of patients will show no response to therapy [8, 9].”
BackgroundCirculating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
Lee, J. H., Long, G. V., Boyd, S., Lo, S., Menzies, A. M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R. A., Mann, G. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx026 · Cited by 333
Acquired and intrinsic resistance in cancer immunotherapy
Kelderman, S., Schumacher, T. N. M., & Haanen, J. B. A. G. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.011 · Cited by 197
Cited by
Cytokines: From Clinical Significance to Quantification
Liu, C., Chu, D., Kalantar‐Zadeh, K., George, J., Young, H. A., & Liu, G. (2021) · Advanced Science · doi:10.1002/advs.202004433 · Cited by 940
Lim, S. Y., Lee, J. H., Gide, T. N., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E. J., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2795 · Cited by 381
Self-citationHigh-throughput proteomics: a methodological mini-review
Cui, M., Cheng, C., & Zhang, L. (2022) · Laboratory Investigation · doi:10.1038/s41374-022-00830-7 · Cited by 370
Katz, D. H., Robbins, J. M., Deng, S., Tahir, U. A., Bick, A. G., Pampana, A., Yu, Z., Ngo, D., Benson, M. D., Chen, Z.-Z., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm5164 · Cited by 206
“Earlier comparisons have been limited by sample size and the number of proteins measured at the time of comparison (16, 17) but did suggest differences in platform characteristics and reproducibility.”
BackgroundTin, A., Yu, B., Ma, J., Masushita, K., Daya, N., Hoogeveen, R. C., Ballantyne, C. M., Couper, D., Rebholz, C. M., Grams, M. E., et al. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2018.027086 · Cited by 106
Metadata
- Authors
- Lim, S. Y., Lee, J. H., Welsh, S. J., Ahn, S. B., Breen, E., Khan, A., Carlino, M. S., Menzies, A. M., Kefford, R. F., Scolyer, R. A., Long, G. V., & Rizos, H.
- Venue
- Biomarker Research
- Published
- 2017-11-10
- Volume
- 5
- Issue
- 1
- Pages
- 32-32
- ISSN
- 2050-7771 (ISSN-L)
- OpenAlex
- W2767744379
- Cited by
- 42
- References
- 7
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. https://app.cochat.ai/papers/10.1186/s40364-017-0112-9
- The paper
- Lim, S. Y., Lee, J. H., Welsh, S. J., Ahn, S. B., Breen, E., Khan, A., Carlino, M. S., Menzies, A. M., Kefford, R. F., Scolyer, R. A., Long, G. V., & Rizos, H. (2017). Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. Biomarker Research. https://doi.org/10.1186/s40364-017-0112-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.